Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 18;18(2):e1003523.
doi: 10.1371/journal.pmed.1003523. eCollection 2021 Feb.

Assessing the impact of preventive mass vaccination campaigns on yellow fever outbreaks in Africa: A population-level self-controlled case series study

Affiliations

Assessing the impact of preventive mass vaccination campaigns on yellow fever outbreaks in Africa: A population-level self-controlled case series study

Kévin Jean et al. PLoS Med. .

Abstract

Background: The Eliminate Yellow fever Epidemics (EYE) strategy was launched in 2017 in response to the resurgence of yellow fever in Africa and the Americas. The strategy relies on several vaccination activities, including preventive mass vaccination campaigns (PMVCs). However, to what extent PMVCs are associated with a decreased risk of outbreak has not yet been quantified.

Methods and findings: We used the self-controlled case series (SCCS) method to assess the association between the occurrence of yellow fever outbreaks and the implementation of PMVCs at the province level in the African endemic region. As all time-invariant confounders are implicitly controlled for in the SCCS method, this method is an alternative to classical cohort or case-control study designs when the risk of residual confounding is high, in particular confounding by indication. The locations and dates of outbreaks were identified from international epidemiological records, and information on PMVCs was provided by coordinators of vaccination activities and international funders. The study sample consisted of provinces that were both affected by an outbreak and targeted for a PMVC between 2005 and 2018. We compared the incidence of outbreaks before and after the implementation of a PMVC. The sensitivity of our estimates to a range of assumptions was explored, and the results of the SCCS method were compared to those obtained through a retrospective cohort study design. We further derived the number of yellow fever outbreaks that have been prevented by PMVCs. The study sample consisted of 33 provinces from 11 African countries. Among these, the first outbreak occurred during the pre-PMVC period in 26 (79%) provinces, and during the post-PMVC period in 7 (21%) provinces. At the province level, the post-PMVC period was associated with an 86% reduction (95% CI 66% to 94%, p < 0.001) in the risk of outbreak as compared to the pre-PMVC period. This negative association between exposure to PMVCs and outbreak was robustly observed across a range of sensitivity analyses, especially when using quantitative estimates of vaccination coverage as an alternative exposure measure, or when varying the observation period. In contrast, the results of the cohort-style analyses were highly sensitive to the choice of covariates included in the model. Based on the SCCS results, we estimated that PMVCs were associated with a 34% (95% CI 22% to 45%) reduction in the number of outbreaks in Africa from 2005 to 2018. A limitation of our study is the fact that it does not account for potential time-varying confounders, such as changing environmental drivers of yellow fever and possibly improved disease surveillance.

Conclusions: In this study, we provide new empirical evidence of the high preventive impact of PMVCs on yellow fever outbreaks. This study illustrates that the SCCS method can be advantageously applied at the population level in order to evaluate a public health intervention.

PubMed Disclaimer

Conflict of interest statement

Tini Garske was the principal investigator of a grant from The Bill & Melinda Gates Foundation, and the principal investigator of a grant from GAVI, both funding the Vaccine Impact Modelling Consortium. Other authors have declared no competing interests. Author Tini Garske was unable to confirm their authorship contributions. On their behalf, the corresponding author has reported their contributions to the best of their knowledge.

Figures

Fig 1
Fig 1. Occurrence of yellow fever outbreaks and preventive mass vaccination campaigns at the province level over the 2005–2018 period.
(A) Yellow fever outbreaks. (B) Preventive mass vaccination campaigns. Maps were produced using GADM version 2.0.
Fig 2
Fig 2. Swimmer plot of the chronology of exposure to preventive mass vaccination campaigns (PMVCs) and yellow fever outbreaks among the 33 African provinces both affected by an outbreak and targeted for a PMVC (2005–2018).
(A) Time distribution of yellow fever outbreaks. (B) Swimmer plot. The 3-letter codes on the y-axis refer to International Organization for Standardization county codes (see S2 Table for complete province and country names).

References

    1. World Health Organization. Yellow fever in Africa and the Americas, 2018. Wkly Epidemiol Rec. 2019;94:365–80.
    1. World Health Organization. Emergencies preparedness, response: disease outbreak news—yellow fever. Geneva: World Health Organization; 2020 [cited 2020 Jul 3]. https://www.who.int/csr/don/archive/disease/yellow_fever/en/.
    1. World Health Organization. Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017–2026. Wkly Epidemiol Rec. 2017;92:193–204. - PubMed
    1. Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, et al.. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11:e1001638. 10.1371/journal.pmed.1001638 - DOI - PMC - PubMed
    1. Shearer FM, Longbottom J, Browne AJ, Pigott DM, Brady OJ, Kraemer MUG, et al.. Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis. Lancet Glob Health. 2018;6:e270–8. 10.1016/S2214-109X(18)30024-X - DOI - PMC - PubMed

Publication types

MeSH terms